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HIV Entry and Its Inhibition Minireview
The details of this conformational changeare only begin-David C. Chan and Peter S. Kim
Whitehead Institute for Biomedical Research ning to be understood, but at least include exposure of
Howard Hughes Medical Institute the ªfusionº peptide at the amino terminus of gp41. By
Department of Biology analogy with the spring-loaded model of influenza virus
Massachusetts Institute of Technology (Carr and Kim, 1993), this fusion-peptide region is
Cambridge, Massachusetts 02142 thought to insert into the target membrane at an early
step of the fusion process. The observation that the HIV
envelope complexreadily undergoes receptor-activated
The human immunodeficiency virus type 1 (HIV-1) is conformational change suggests that its native state is
an enveloped virus, and its envelope protein complex metastable, again similar to the pH-activated envelope
controls the key process of viral entry. This envelope protein of influenza virus (Carr et al., 1997). That is,
protein determines viral tropism and facilitates themem- the labile native state of the HIV envelope complex is
brane fusion process that allows invasion of the viral transformed by receptor binding to an energetically
genome. The envelope protein can also promote the more stable, fusion-active conformation.
fusion of infected cells with uninfected neighboring Protein dissection studies demonstrated that the two
cells, a phenomenon called syncytium formation that is 4,3 hydrophobic repeat regions within gp41 form a heli-
readily observed in cultured cells and may be responsi- cal trimer of antiparallel dimers (Lu et al., 1995). Crystal-
ble for some of the cytopathic effects of advanced HIV lographic analysis confirmed that this gp41 core is a
infection. Here we review recent insights in HIV envelope six-helix bundle in which the N and C helices are ar-
protein structure and function and present our current ranged into three hairpins (Figures 1B and 1C) (Chan et
understanding of the entry process. We also review how al., 1997; Weissenhorn et al., 1997). The N peptides form
these findings lead to new approaches for inhibiting HIV three central helices arranged in a trimeric coiled coil.
entry and may provide insights into the design of better The C peptides form three outer helices that pack in an
HIV vaccines. antiparallel manner into highly conserved, hydrophobic
The HIV-1 envelope protein complex is initially pro- grooves on the surface of this coiled coil (Figure 1D).
duced as the precursor gp160, which is extensively gly- This structure likely represents the fusion-active confor-
cosylated and proteolytically cleaved into two subunits mation of gp41 (see discussion in Chan et al., 1997), and
by a cellular convertase (Luciw, 1996). The resulting resembles the proposed fusion-active conformations of
surface subunit (gp120) and transmembrane subunit the transmembrane envelope proteins from influenza
(gp41) remain noncovalently associated and oligomer- virus and Moloney murine leukemia virus.
ize, most likely as trimers, on the surface of the virion. Fusion Mechanism
gp120 binds to CD4 and a coreceptor (a seven-trans-
Any model for HIV entry must account for the remarkable
membrane protein of the chemokine receptor family),
observation that synthetic C peptides inhibit HIV infec-
which are present on susceptible cells such as T lym-
tion and syncytia formation at nanomolar concentra-
phocytes and macrophages. Subsequently, gp41 under-
tions (Jiang et al., 1993; Wild et al., 1994). Preincubation
goes conformational changes that mediate fusion of the
of virus with C peptide, followed by its removal, does
viral membrane with the target cell membrane. HIV entry
not block HIV entry; this feature suggests that theseis therefore a complex process involving multiple protein
peptides do not act on the native conformation of gp41.interactions, each of which is a potential target for the
Based on the structural features of the fusion-activedevelopment of antiviral compounds.
gp41 core, these peptide inhibitors likely work by bind-gp41 Structure
ing to the trimeric coiled coil of gp41, thereby actingThe gp41 molecule is a transmembrane protein with
through a dominant-negative mechanism (Lu et al.,several important features within its ectodomain (Figure
1995; Chan et al., 1997; Weissenhorn et al., 1997).1A). First, the amino terminus of gp41, created by pro-
A simple dominant-negative model, however, fails toteolytic cleavage of the gp160 precursor, contains a
explain adequately one puzzling feature of C peptidehydrophobic, glycine-rich ªfusionº peptide that is essen-
inhibition: How can C peptides act at such low concen-tial for membrane fusion. Second, there are two regions
trations, given that the N and C peptide regions arewith a 4,3 hydrophobic (heptad) repeat, a sequence mo-
within a single gp41 molecule? That is, how can the Ctif characteristic of coiled coils. Synthetic peptides (see
peptides so effectively inhibit an intramolecular associa-below) derived from these two regions are termed N
tion reaction, in which the two regions of gp41 are pres-(amino-terminal) and C (carboxy-terminal) peptides. Be-
ent in a high effective concentration? It seems likely thattween these two heptad repeat regions is a loop region
the solution to this puzzle is that C peptides must bindcontaining two cysteines.
to gp41 prior to formation of the six-helix complex be-A large number of studies support the notion that the
cause, once this gp41 core is assembled, it is extremelyenvelope complex exists in at least two major conforma-
stable (the melting temperature of the gp41 core is intions (see references in Chan et al., 1997). The native,
excess of 908C) and is unlikely to be disrupted by exoge-or nonfusogenic, conformation exists on the surface
nous peptides. These observations suggest the exis-of free virions after budding from infected cells. Upon
tence of a transiently populated, third state of gp41. Cbinding of gp120 to target cell receptors, gp41 under-
goes a conformational change to a fusion-active state. peptides act at this intermediate stage, after the native
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Figure 1. HIV gp41 Structure
(A) A schematic view of gp41, showing the
location of the fusion peptide (fp), the two
hydrophobic heptad repeats, the transmem-
brane segment (tm), and the cytoplasmic re-
gion (cyto). The location of various gp41 pep-
tides are shown above. The locations of the
three residues that bind the cavity in the cen-
tral coiled coil (D) are indicated by red bars.
(B and C) A ribbon diagram of the N36/C34
complex (which forms the core of the gp41
ectodomain) viewed looking down the 3-fold
axis (B) and from the side (C). The N36 helices
(gray) form a central, trimeric coiled coil, and
three antiparallel C34 helices (blue) wrap
obliquely around this coiled coil. (D) Repre-
sentation of the N36 coiled coil as a molecular
surface (gray), with the three C34 helices
(blue and red) depicted as rods. The C34 heli-
ces pack against a conserved groove on the
surface of the coiled coil. The bottom of the
coiled coil has a large cavity that provides a
binding pocket for three C34 residues (red).
state has undergone a conformational transition but be- and is then relatively stable, with a lifetime of many
minutes. Video microscopy and the fluorescent dye bis-fore formation of the hairpin structure. In this ªprehair-
pinº intermediate, the N and C peptide regions are not ANS have been used to monitor the kinetics of receptor-
activated conformational changes (Jones et al., 1998).associated, allowing synthetic C peptides to bind to the
N peptide region of gp41 and inhibit transition to the These studies indicate that conformational changes are
initiated within 1±4 min of receptor binding and are com-fusion-active conformation (Figure 2).
The prehairpin intermediate appears to be induced plete within 20 min, well before any evidence of lipid
mixing. Significantly, C peptides retain much of theirrapidly upon interaction of gp120 with cellular receptors
Figure 2. Model of HIV Membrane Fusion
In the native state of the trimeric gp120 (green)/gp41 (blue/gray shading) complex, the fusion peptide (not shown) is buried. Upon interaction
of gp120 with cellular receptors, the envelope complex undergoes a conformational change to the prehairpin intermediate, in which the fusion
peptide (red lines) is inserted into the target membrane and the N peptide region (gray) is a trimeric coiled coil. The C peptide region (blue)
has not yet associated with the N peptide coiled coil because of a kinetic block due to association with either another portion of gp41, or
more likely, gp120. This intermediate is relatively long-lived (many minutes) and is vulnerable to C peptide inhibition (bottom). The prehairpin
intermediate resolves to the fusion-active hairpin structure when the C peptide region binds to the N peptide coiled coil and adopts a helical
conformation. This rearrangement results in membrane apposition. The interactions necessary for fusion are unknown (as indicated by ª?º),
but may involve aggregation of gp41 trimers to form fusion pores. After fusion is completed, the fusion peptide and the transmembrane
segment (purple lines) of gp41 lie within the same membrane. The steps at which various HIV entry inhibitors act are shown.
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inhibitory activity against membrane fusion when added more difficult to select for viruses resistant to T649 (Fig-
ure 1A), a C peptide that contains the cavity bindingafter these rapid conformational changes (Munoz-Bar-
roso et al., 1998). region (Rimsky et al., 1998). Steps toward the develop-
ment of more potent versions of C peptides have begunTaken together, these observations suggest the fol-
lowing model for gp41-mediated membrane fusion (Fig- (Judice et al., 1997).
Targeting Cellular Receptorsure 2) (for related models, see Hughson, 1997; Weis-
senhorn et al., 1997; Furuta et al., 1998). In free virions, Early work targeting cellular receptors focused on using
soluble versions of CD4 as HIV entry inhibitors. Thisgp41 exists in a native, nonfusogenic conformation in
which the fusion peptides are buried within the envelope approach, while effective against laboratory-adapted
HIV strains in vitro, has proved ineffective on primarycomplex. This gp41 structure is stabilized by its interac-
tions with gp120. When gp120 binds to cell-surface CD4 HIV isolates. The identification of the chemokine recep-
tors as essential cofactors has led to new targets forand a chemokine receptor, a conformational change
occurs in gp120 that alters gp120±gp41 interactions. inhibition of viral entry. The chemokines themselves,
or variants thereof, form a potent class of inhibitorsThis perturbation of the gp120±gp41 interaction triggers
gp41 to undergo its transition to the prehairpin interme- (reviewed in Littman, 1998). HIV strains that use the
CCR5 coreceptors are blocked by the CCR5 ligandsdiate. These changes in gp41 include exposure of the
fusion peptide and its insertion into the target mem- RANTES, MIP-1a, and MIP-1b; likewise, strains that use
the CXCR4 coreceptor are blocked by the CXCR4 ligandbrane. We imagine that the prehairpin intermediate pen-
etrates the target membrane with its fusion peptide, SDF (stromal-derived factor). These factors appear to
work through two mechanisms. First, they competitivelywhich lies on top of the N peptide coiled coil. The C
peptide region is not associated with this coiled coil, block interaction of gp120 with the chemokine recep-
tors. Second, they down-regulate chemokine receptorperhaps because it is constrained by an interaction with
another region of gp41, or more likely, gp120. This pre- expression in the target cells, thereby limiting the num-
ber of HIV entry points.hairpin intermediate represents the vulnerable target of
C peptide inhibition. Consistent with this view, the C Progress has already been made in identifying small-
molecule inhibitors of the chemokine receptors (seepeptide DP178 binds to gp41 only after interaction of
the envelope complex with cellular receptors (Furuta et references in Littman, 1998). Two such compounds,
ALX40-4C and T22, are short, positively charged pep-al., 1998).
The resolution of this intermediate to the six-helix tides. A third, called AMD3100, is a bicyclam compound.
All three of these compounds inhibit entry of HIV strainscomplex may be slow because the constraints holding
the C peptide region are slow to dissociate. Moreover, that utilize CXCR4 as a coreceptor and likely work by
binding directly to CXCR4, thereby blocking its interac-there are topological constraints that prevent a simple,
symmetric transition from the prehairpin intermediate tion with gp120.
Eliciting Neutralizing Antibodiesto the six-helix structure. Once these constraints are
overcome, association of the C peptide region with the The need for an HIV vaccine remains urgent, and many
past efforts have focused on eliciting a neutralizing anti-N peptide coiled coil leads to formation of the fusion-
active hairpin structure and the local apposition of viral body response against the envelope complex (reviewed
in Burton, 1997; Haynes, 1996). Passive transfer of highand cellular membranes. How membrane apposition
leads to complete fusion is unclear but may involve levels of neutralizing monoclonal antibodies has been
shown in animal models to protect against a virus chal-clustering of envelope protein trimers to form fusion
pores. After fusion is complete, the fusion peptide and lenge. The ability of live-attenuated SIV vaccines to pro-
tect macaques from a challenge virus in the absence ofthe transmembrane segment of gp41 lie in the same
membrane (Figure 2). Recent work suggests that, in a a strong neutralizing antibody response suggests that
other mechanisms, including cell-mediated immunity,manner analogous to viral entry, fusion between cellular
membranes mediated by t-SNARE and v-SNARE protein are capable of providing protection. The importance of
generating T cell responses to HIV is well recognized,complexes also involves helical structures to appose
two membranes for fusion (Weber et al., 1998). but we restrict our discussion to approaches for eliciting
neutralizing antibodies to HIV.gp41-Derived Peptides Are Potent
Fusion Inhibitors Human vaccine trials using monomeric gp120 as an
immunogen have yielded disappointing results (VanCottIn the gp41 core, each of the outer C helices binds along
a conserved groove on the surface of the central coiled et al., 1995; Haynes, 1996; Bolognesi and Matthews,
1998; Connor et al., 1998). Individuals immunized withcoil. The broad inhibitory activity of C peptides against
diverse HIV isolates is explained by thehighly conserved monomeric gp120 show low levels of neutralizing anti-
bodies that are effective only against the HIV strains tonature of the hydrophobic groove to which these pep-
tides bind. Toward the bottom of the groove is a deep which they were immunized, and not to primary isolates.
Preparations of gp120 used in early vaccination trialscavity that is filled by three hydrophobic residues from
the C helix (Figure 1D). This pocket is potentially a good were derived from laboratory-adapted HIV strains, which
are now known to be substantially more sensitive totarget for inhibiting HIV invasion (Chan et al., 1997), al-
though peptides lacking the cavity-occupying residues neutralization than primary clinical isolates (Mascola et
al., 1996). Perhaps most telling, antibody responses in(e.g., DP-178; see Figure 1A) can still be potent inhibi-
tors. As may be expected, mutant viruses that escape gp120-vaccinated individuals are often directed against
linear epitopes exposed on denatured gp120 but notDP178 inhibition bear mutations in the N peptide region
of gp41 (Rimsky et al., 1998). Interestingly, it is much correctly folded gp120 (VanCott et al., 1995). In marked
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Chan, D.C., Fass, D., Berger, J.M., and Kim, P.S. (1997). Cell 89,et al., 1995).
263±273.It is questionable whether even natural HIV infection
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Walker, B.D., Neumann, A.U., Vermund, S.H., Mestecky, J., Jackson,passive transfer of pooled Ig from seropositive donors
S., et al. (1998). J. Virol. 72, 1552±1576.
fails to lower viral titers in infected humans. Even in
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cases where vaccinees show reactivity to folded, mono- Biol. 5, 276±279.
meric gp120 (Connor et al., 1998), there is as yet no Haynes, B.F. (1996). Lancet 348, 933±937.
direct evidence for binding to the oligomeric envelope
Hughson, F.M. (1997). Curr. Biol. 7, R565±R569.
protein on the surface of clinical HIV isolates. Therefore,
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the challenge at hand for vaccine developers is formida- 113.
ble: to elicit an antibody response that is more effective Jones, P.L., Korte, T., and Blumenthal, R. (1998). J. Biol. Chem. 273,
than that obtained through a natural HIV infection. 404±409.
Unfortunately, broad-spectrum neutralization epitopes Judice, J.K., Tom, J.Y., Huang, W., Wrin, T., Vennari, J., Petropoulos,
on the envelope complex appear to be rare and poorly C.J., and McDowell, R.S. (1997). Proc. Natl. Acad. Sci. USA 94,
13426±13430.immunogenic, perhaps because they are efficiently
masked by numerous carbohydrates. Only three human Littman, D.R. (1998). Cell 93, this issue, 677±680.
monoclonal antibodies capable of efficient, broad-spec- Lu, M., Blacklow, S.C., and Kim, P.S. (1995). Nat. Struct. Biol. 2,
1075±1082.trum neutralization of HIV infectivity have been isolated.
Two of these monoclonal antibodies (b12 and 2G12) Luciw, P.A. (1996). In Fields Virology (Philadelphia: Lippincott-Raven
Publishers), pp. 1881±1952.bind to distinct epitopes on gp120, whereas the third
Mascola, J.R., Snyder, S.W., Weislow, O.S., Belay, S. M., Belshe,(2F5) recognizes a region of gp41 close to the transmem-
R.B., Schwartz, D.H., Clements, M.L., Dolin, R., Graham, B.S., Gorse,brane region. These epitopes are poorly immunogenic,
G.J., et al. (1996). J. Infect. Dis. 173, 340±348.since monoclonal antibodies to them have been isolated
Munoz-Barroso, I., Durell, S., Sakaguchi, K., Appella, E., and Blu-only once from individual donors. Clearly, the envelope
menthal, R. (1998). J. Cell Biol. 140, 315±323.
proteins of HIV have evolved to evade the human im-
Rimsky, L.T., Shugars, D.C., and Matthews, T.J. (1998). J. Virol. 72,mune system. Indeed, most of the humoral response to
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a natural HIV infection appears to be directed against
VanCott, T.C., Bethke, F.R., Burke, D.S., Redfield, R. R., and Birx,
forms of the envelope protein that are not present on D.L. (1995). J. Immunol. 155, 4100±4110.
the native virus; the reasons for this are unknown, but Weber, T., Zemelman, B.V., McNew, J.A., Westermann, B., Gmachl,
it has been suggested that viral debris is a dominant M., Parlati, F., SoÈ llner, T.H., and Rothman, J.E. (1998). Cell 92,
immunogen that may serve as a decoy (Burton, 1997). 759±772.
Looking ahead, there is a clear need to develop enve- Weissenhorn, W., Dessen, A., Harrison, S.C., Skehel, J.J., and Wiley,
D.C. (1997). Nature 387, 426±430.lope protein preparations, based on primary isolates,
that have a correctly folded conformation and oligomer- Wild, C.T., Shugars, D.C., Greenwell, T.K., McDanal, C.B., and Mat-
thews, T.J. (1994). Proc. Natl. Acad. Sci. USA 91, 9770±9774.ization state. Since the unprocessedenvelope precursor
is different from the mature protein, these preparations
should be processed to gp120/gp41. However, this mat-
uration-cleavage step presents another problem: gp120
is readily ªshedº from gp41. Shedding was also a prob-
lem with early whole-killed (inactivated) HIV prepara-
tions, and methods for cross-linking envelope protein
subunits may prove crucial. Similar considerations apply
to pseudotyped-virus preparations, such as the ca-
narypox virus vaccine candidate (see Bolognesi and
Matthews, 1998).
Finally, it remains possible that, even with optimized
envelope protein preparations, these vaccines will gen-
erate only strain-restricted responses because broadly
neutralizing epitopes are rare and poorly immunogenic.
In this case, it may be necessary to resort to cocktails
of envelope proteins from selected primary isolates. It
seems almost certain, however, that the challenge of
eliciting broadly neutralizing antibodies to HIV will re-
quire close attention to issues of protein structure and
conformation in vaccine candidates.
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